The Potential Role of Compounds Derived From Ultra-processed Foods in Pathogenesis of Eosinophilic Esophagitis

Overview

Eosinophilic esophagitis (EoE) is a chronic antigen-mediated inflammatory disease of the esophagus that affects both children and adults. The incidence and prevalence of EoE is rapidly increasing in Western countries with an estimated incidence of 6.6 per 100,000 person-years (95% CI, 3-11.7) in children and 7.7 per 100,000 person-years (95% CI, 1.8-17.8) in adults. Clinically, it is characterized by various symptoms related to esophageal dysfunction, including vomiting, regurgitation, feeding difficulties, epigastric heartburn, dysphagia, or food bolus impaction, and may cause growth retardation. Diagnosis is made on the basis of clinical symptoms and histological evidence of eosinophilic infiltration of the esophagus (at least 15 eosinophils/high power microscope field (eos /hpf), excluding other etiologies of esophageal eosinophilia (gastroesophageal reflux disease, infectious esophagitis, achalasia, celiac disease and Crohn's disease, connective tissue disorders, gra ft versus host disease, drug hypersensitivity and hypereosinophilic syndromes). EoE is primarily characterized by a T helper 2 type inflammation, but the pathogenesis and the immunopathological mechanisms underlying the pathology are not yet fully understood. Recent evidence suggests that in genetically predisposed individuals, interaction with environmental factors (e.g., dietary lifestyle) may play a role in activating several inflammatory pathways and cause EoE. Ultra-processed foods (UPFs) are food and beverage products resulting from industrial formulations, ready for consumption, typically obtained with five or more ingredients from different manufacturing processes (cooking methods, addition of additives such as stabilizers or preservatives). During the last decade, the consumption of the latter has increased significantly among the pediatric population to represent 30% of the daily caloric intake of an average child in Europe and America. Recent evidences show that UPFs favor the onset of chronic non-communicable diseases through the activation of different inflammatory pathways. The components mostly represented in UPFs are the advanced glycation end products (AGEs), a heterogeneous group of highly oxidizing compounds that are formed through non-enzymatic reactions (Maillard reaction) between reduced sugars and free amino groups of proteins, lipids, or nucleic acids. Evidence demonstrates that dietary AGEs are absorbed and contribute significantly to the total concentration of AGEs in the body. AGEs induce oxidative stress and inflammation, leading to structural and functional protein alterations, cellular apoptosis and multi-tissue/organ damage. These mechanisms are mediated at least in part by interactions with their cell-surface receptor for advanced glycation end-products (RAGE). The AGEs-RAGE interaction modulates the immune response. AGEs are able to activate le mast cells, to stimulate the release of histamine and to induce a chronic inflammatory state that promotes a T helper 2 type response.

Interventions

• Other Dietary evaluation
  Comparative evaluation of the dietary consumption of ultraprocessed foods and ultraprocessed foods-derived compounds

Primary outcome measures

• Comparative evaluation of the dietary consumption of Ultraprocessed Foods [Time frame: At enrollment]

Secondary outcome measures (8)

• Intake of dietary Advanced Glycation End-products [Time frame: At enrollment]
• Skin Advanced Gycation End-products accumulation level [Time frame: At enrollment]
• Advanced Glycation End-Products receptor (RAGE) expression in peripheral blood mononuclear cells (PBMCs) [Time frame: At enrollment]
• Advanced Glycation End-Products receptor (RAGE) expression in plasma [Time frame: At enrollment]
• Advanced Glycation End-Products receptor (RAGE) expression in peripheral blood mononuclear cells (PBMCs) [Time frame: At enrollment]
• Disease severity [Time frame: At 3 months, at 6 months]
• Disease severity [Time frame: At 3 months, at 6 months]
• Treatment response [Time frame: At 3 months, at 6 months]

Eligibility criteria

Inclusion criteria

• both sexes
• age between 3-65 years
• sure diagnosis of eosinophilic esophagitis
• age- and sex-matched healthy controls
• parents/tutor written informed consent.

Exclusion criteria

• lack of written informed consent;
• non-Caucasian ethnicity
• age at enrollment < 3 or >65 years
• simultaneous presence of other chronic diseases: eosinophilic gastroenteritis, eosinophilic colitis, achalasia, GERD, hypereosinophilia syndrome, IBD, fungal or viral infections, connective tissue disorders, autoimmune diseases, vasculitis, bullous dermatosis with oesophageal involvement (pemphigus), drug hypersensitivity reactions, drug-induced oesophagitis, graft vs host disease, monogenic disorders (Marfan syndrome type 2, HIES, PTEN).
• presence of tattoos, scars, moles or particular lesions on both forearms

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model

Case-control

Study locations

Italy · 2 centers

• Department of Traslational Medical Science - University of Naples Federico II — Naples
• Department of Traslational Medical Science - University of Naples Federico II — Naples

Identifiers

NCT: NCT06093204 · 00014834

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗